Specimatch, the first continual clinical trial monitoring service announces the launch of its web-based software service for cancer patients. Users can easily connect to clinical trials personally matched to the patient’s genetic and clinical profiles through Specimatch.com.
This software is a solution for patients and oncologists to tap into a complex landscape of breakthrough treatments with both accuracy and simplicity.
It alleviates the gaps in care by putting the power of precision medicine in the hands of patients and the doctors with whom they partner in the fight against cancer.
Using Specimatch ‘continual 24/7 monitoring’, it would be easy to identify matching trials in real time, based on a user-completed clinical and genetic profile. Cancer patients will meet their match and survival rates will enhance.
Clinical trials are the key drivers in bringing cancer breakthroughs to market, yet 75 percent of investigators fail to enroll the targeted amount of patients per trial despite hundreds of millions of dollars in spending per trial.
Approximately 85 percent of U.S. Cancer patients lack access to these opportunities although trials offer first access to cutting-edge precision treatments. And only 3 percent are successfully placed into trials.
